WO2008090850A1 - 抗癌剤の効果増強剤 - Google Patents

抗癌剤の効果増強剤 Download PDF

Info

Publication number
WO2008090850A1
WO2008090850A1 PCT/JP2008/050727 JP2008050727W WO2008090850A1 WO 2008090850 A1 WO2008090850 A1 WO 2008090850A1 JP 2008050727 W JP2008050727 W JP 2008050727W WO 2008090850 A1 WO2008090850 A1 WO 2008090850A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
effect
anticancer
enhancing
anticancer agent
Prior art date
Application number
PCT/JP2008/050727
Other languages
English (en)
French (fr)
Inventor
Eisuke Mekada
Shingo Miyamoto
Original Assignee
Juridical Foundation Osaka Industrial Promotion Organization
Osaka University
Fukuoka University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juridical Foundation Osaka Industrial Promotion Organization, Osaka University, Fukuoka University filed Critical Juridical Foundation Osaka Industrial Promotion Organization
Publication of WO2008090850A1 publication Critical patent/WO2008090850A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本発明は、アンフィレギュリン阻害剤を有効成分として含有することを特徴とする抗癌剤の効果増強剤であり、該効果増強剤は抗癌剤と併用することにより、抗癌剤単独で使用する場合に較べて、抗癌剤の抗癌作用を顕著に増強することができる。
PCT/JP2008/050727 2007-01-22 2008-01-21 抗癌剤の効果増強剤 WO2008090850A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007011939 2007-01-22
JP2007-011939 2007-01-22

Publications (1)

Publication Number Publication Date
WO2008090850A1 true WO2008090850A1 (ja) 2008-07-31

Family

ID=39644426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/050727 WO2008090850A1 (ja) 2007-01-22 2008-01-21 抗癌剤の効果増強剤

Country Status (1)

Country Link
WO (1) WO2008090850A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532100A (ja) * 2012-10-05 2015-11-09 バイオニア コーポレイション アンフィレギュリンに特異的な二重鎖オリゴｒｎａ、そのような二重鎖オリゴｒｎａを含む二重鎖オリゴｒｎａの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CASTILLO J. ET AL.: "Amphiregulin Contributes to the Transformed Phenotype of Human Hepatocellular Carcinoma Cells", CANCER RESEARCH, vol. 66, no. 12, 2006, pages 6129 - 6138, XP055244981, DOI: doi:10.1158/0008-5472.CAN-06-0404 *
DAMSTRUP L. ET AL.: "Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis", BRITISH JOURNAL OF CANCER, vol. 80, no. 7, 1999, pages 1012 - 1019, XP002291321, DOI: doi:10.1038/sj.bjc.6690456 *
GSCHWIND A. ET AL.: "TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells", EMBO JOURNAL, vol. 22, no. 10, 2003, pages 2411 - 2421, XP002242854, DOI: doi:10.1093/emboj/cdg231 *
HURBIN A. ET AL.: "Inhibition of Apoptosis by Amphiregulin via an Insulin-like Growth Factor-1 Receptor-dependent Pathway in Non-small Cell Lung Cancer Cell Lines", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 51, 2002, pages 49127 - 49133, XP002474058, DOI: doi:10.1074/jbc.M207584200 *
WILLMARTH N.E. ET AL.: "Autocrine and Juxtacrine Effects of Amphiregulin on the Proliferative, Invasive, and Migratory Properties of Normal and Neoplastic Human Mammary Epithelial Cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 49, 2006, pages 37728 - 37737 *
YOTSUMOTO F. ET AL.: "Validation of HG-EGF and amphiregulin as targets for human cancer therapy", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 365, no. 3, 2008, pages 555 - 561, XP022372618, DOI: doi:10.1016/j.bbrc.2007.11.015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532100A (ja) * 2012-10-05 2015-11-09 バイオニア コーポレイション アンフィレギュリンに特異的な二重鎖オリゴｒｎａ、そのような二重鎖オリゴｒｎａを含む二重鎖オリゴｒｎａの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物

Similar Documents

Publication Publication Date Title
WO2009089494A3 (en) Pharmaceutical compositions
WO2008070268A3 (en) Pharmaceutical compositions
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2008033562A3 (en) Kinase inhibitor compounds
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2012019426A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2009156462A3 (en) Organic compounds
WO2007115821A3 (en) Organic compounds
WO2009077443A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2007077560A3 (en) Cryoprotective compositions and methods of using same
MX2010004576A (es) Derivados de pirimidina novedosos.
WO2012019430A8 (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
WO2009077497A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2012065019A3 (en) Combination comprising pyridopyrimidinone inhibitors of pi3k alpha
WO2009077500A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
WO2010049454A3 (en) Antimicrobial composition from copepods
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
WO2008025819A3 (en) Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability
WO2012071520A3 (en) Fungicidal compositions and methods
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08703577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08703577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP